转移性肾细胞癌患者使用舒尼替尼的交替给药方案。
Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.
作者信息
Kalra S, Rini B I, Jonasch E
机构信息
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, USA.
出版信息
Ann Oncol. 2015 Jul;26(7):1300-4. doi: 10.1093/annonc/mdv030. Epub 2015 Jan 26.
Abstract
Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor exhibiting antiangiogenic activity. Sunitinib demonstrated improved outcomes in comparison to interferon-α in a large phase III study of treatment naïve patients with metastatic renal cell carcinoma. Maintaining patients on sunitinib treatment is essential for a sustained disease control as higher exposure to sunitinib has been associated with an improved overall response rate, progression-free survival and overall survival. Various studies have compared the outcomes of patients undergoing sunitinib therapy based on modifications from their standard dose and schedule. Several studies have shown that switching to an alternate schedule with more frequent dose interruptions without affecting dose density over a 6-week cycle is associated with improved outcomes and increased tolerability.
摘要
苹果酸舒尼替尼是一种口服多靶点酪氨酸激酶抑制剂，具有抗血管生成活性。在一项针对初治转移性肾细胞癌患者的大型III期研究中，舒尼替尼与α干扰素相比显示出更好的疗效。维持患者接受舒尼替尼治疗对于持续控制疾病至关重要，因为更高的舒尼替尼暴露量与改善的总缓解率、无进展生存期和总生存期相关。多项研究根据标准剂量和给药方案的调整比较了接受舒尼替尼治疗患者的疗效。几项研究表明，在6周周期内改为更频繁剂量中断但不影响剂量密度的替代给药方案与改善疗效和提高耐受性相关。
相似文献
1
Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.转移性肾细胞癌患者使用舒尼替尼的交替给药方案。
Ann Oncol. 2015 Jul;26(7):1300-4. doi: 10.1093/annonc/mdv030. Epub 2015 Jan 26.
2
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌的对比研究
N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044.
3
Sunitinib malate for the treatment of renal cell carcinoma.苹果酸舒尼替尼治疗肾细胞癌。
Expert Opin Pharmacother. 2012 Jun;13(9):1323-36. doi: 10.1517/14656566.2012.689130.
4
Alternative sunitinib schedules in metastatic renal cell carcinoma and the RAINBOW study.转移性肾细胞癌中舒尼替尼的替代给药方案及RAINBOW研究
Ann Oncol. 2015 Jul;26(7):1512-3. doi: 10.1093/annonc/mdv168. Epub 2015 Apr 6.
5
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.对于接受口服激酶抑制剂治疗晚期肾细胞癌的患者，需要频繁中断剂量。
Am J Clin Oncol. 2010 Jun;33(3):217-20. doi: 10.1097/COC.0b013e3181a650a6.
6
The use of sunitinib in renal cell carcinoma: where are we now?舒尼替尼在肾细胞癌中的应用：我们目前处于什么阶段？
Expert Rev Anticancer Ther. 2014 Sep;14(9):983-99. doi: 10.1586/14737140.2014.941815. Epub 2014 Jul 28.
7
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.舒尼替尼治疗转移性肾细胞癌日本患者的 II 期研究的总生存和更新结果。
Jpn J Clin Oncol. 2010 Dec;40(12):1166-72. doi: 10.1093/jjco/hyq146. Epub 2010 Aug 16.
8
Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.舒尼替尼治疗转移性肾细胞癌患者的替代剂量方案。
Crit Rev Oncol Hematol. 2014 Dec;92(3):208-17. doi: 10.1016/j.critrevonc.2014.07.006. Epub 2014 Aug 6.
9
Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.血液学参数在转移性肾细胞癌患者中的预后和预测价值：α干扰素治疗后二线使用舒尼替尼。
Asian Pac J Cancer Prev. 2013;14(3):2101-5. doi: 10.7314/apjcp.2013.14.3.2101.
10
Pazopanib outscores sunitinib on tolerability.帕唑帕尼在耐受性方面优于舒尼替尼。
Cancer Discov. 2014 Jan;4(1):OF8. doi: 10.1158/2159-8290.CD-NB2013-131. Epub 2013 Sep 19.
引用本文的文献
1
Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis.比较转移性肾细胞癌一线治疗的疗效和安全性：一项贝叶斯网络Meta回归分析。
Front Oncol. 2023 Feb 22;13:1072634. doi: 10.3389/fonc.2023.1072634. eCollection 2023.
2
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.EVESOR 试验的临床结果，这是一项评估依维莫司和索拉非尼联合用于实体瘤的多参数 I 期临床试验。
Cancer Chemother Pharmacol. 2023 May;91(5):361-373. doi: 10.1007/s00280-023-04508-9. Epub 2023 Feb 25.
3
Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp.由CYP2J2/3A4和BCRP/P-gp介导的利伐沙班与酪氨酸激酶抑制剂之间药物相互作用的风险评估及分子机制研究
Front Pharmacol. 2022 Aug 22;13:914842. doi: 10.3389/fphar.2022.914842. eCollection 2022.
4
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point.舒尼替尼在转移性肾细胞癌患者中的适应性给药：计算机模拟建模如何助力更快找到关键要点
Cancer Chemother Pharmacol. 2022 Apr;89(4):565-569. doi: 10.1007/s00280-021-04383-2. Epub 2022 Feb 11.
5
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.免疫检查点抑制剂治疗与晚期肾细胞癌靶向治疗后的无治疗生存：CheckMate 214 试验的 42 个月结果。
Clin Cancer Res. 2021 Dec 15;27(24):6687-6695. doi: 10.1158/1078-0432.CCR-21-2283. Epub 2021 Nov 10.
6
Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study.在转移性肾细胞癌患者中，采用4/2方案与2/1方案给予舒尼替尼的耐受性和疗效：一项前瞻性随机多中心埃及研究。
Contemp Oncol (Pozn). 2020;24(4):221-228. doi: 10.5114/wo.2020.102802. Epub 2021 Jan 4.
7
Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.一线治疗转移性肾细胞癌的系统治疗：系统评价和网络荟萃分析。
Cancer Immunol Immunother. 2021 Feb;70(2):265-273. doi: 10.1007/s00262-020-02684-8. Epub 2020 Aug 5.
8
Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis.瑞典转移性肾细胞癌靶向治疗的真实世界成本效益：一项基于人群的回顾性分析。
Cancer Manag Res. 2019 Feb 8;11:1289-1297. doi: 10.2147/CMAR.S188849. eCollection 2019.
9
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.纳武利尤单抗联合伊匹单抗与舒尼替尼一线治疗中低危晚期肾细胞癌的成本效果分析。
Oncologist. 2019 Mar;24(3):366-371. doi: 10.1634/theoncologist.2018-0656. Epub 2019 Feb 1.
10
Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.每周或每两周一次高剂量舒尼替尼治疗难治性实体瘤患者的 I 期剂量递增研究。
J Clin Oncol. 2019 Feb 10;37(5):411-418. doi: 10.1200/JCO.18.00725. Epub 2018 Dec 26.
本文引用的文献
1
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.舒尼替尼的 2 周给药、1 周停药方案与转移性肾细胞癌的毒性降低有关。
Eur J Cancer. 2014 Apr;50(6):1084-9. doi: 10.1016/j.ejca.2014.01.025. Epub 2014 Feb 19.
2
Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.舒尼替尼给药方案调整为 2 周用药、1 周停药在转移性肾细胞癌患者中的耐受性更好--与标准 4 周用药、2 周停药方案比较。
Jpn J Clin Oncol. 2014 Mar;44(3):270-7. doi: 10.1093/jjco/hyt232. Epub 2014 Jan 27.
3
Axitinib in Metastatic Renal Cell Carcinoma.阿昔替尼用于转移性肾细胞癌
Biol Ther. 2012 Oct 16;2(1):5. doi: 10.1007/s13554-012-0005-2. eCollection 2012.
4
Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.接受个体化舒尼替尼治疗的转移性肾细胞癌患者的疗效：与动态微泡超声数据的相关性及文献综述
Urol Oncol. 2014 May;32(4):480-7. doi: 10.1016/j.urolonc.2013.10.004. Epub 2013 Dec 8.
5
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.阿昔替尼加或不加剂量滴定用于一线转移性肾细胞癌：一项随机双盲 2 期试验。
Lancet Oncol. 2013 Nov;14(12):1233-42. doi: 10.1016/S1470-2045(13)70464-9. Epub 2013 Oct 18.
6
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.接受替西罗莫司替代舒尼替尼治疗的转移性肾细胞癌患者的临床结局。
J Urol. 2014 Mar;191(3):611-8. doi: 10.1016/j.juro.2013.08.090. Epub 2013 Sep 7.
7
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.一项转移性透明细胞肾细胞癌中血管内皮生长因子靶向治疗停药的前瞻性评估。
Ann Oncol. 2013 Aug;24(8):2098-103. doi: 10.1093/annonc/mdt130. Epub 2013 Apr 11.
8
Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients.双周舒尼替尼方案可减少转移性肾细胞癌的毒性并保持疗效：单中心 31 例患者的经验。
Int J Urol. 2013 May;20(5):478-83. doi: 10.1111/j.1442-2042.2012.03204.x. Epub 2012 Nov 1.
9
Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma.患者将毒性与二线治疗晚期肾细胞癌的无进展生存期进行权衡。
J Med Econ. 2012;15(6):1139-48. doi: 10.3111/13696998.2012.708689. Epub 2012 Jul 18.
10
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.舒尼替尼治疗肾癌患者停药后快速血管生成。
Clin Cancer Res. 2012 Jul 15;18(14):3961-3971. doi: 10.1158/1078-0432.CCR-12-0002. Epub 2012 May 9.
Zotero 插件